Hologic Faces Merger-Related Stockholder Suits, Issues Disclosures

Hologic ( (HOLX) ) has provided an update.

Hologic, Inc. has disclosed that stockholder litigation and demand letters have been filed in January 2026 challenging disclosures in its proxy materials for the planned merger with Hopper Parent Inc., alleging material omissions and seeking to block the shareholder vote, prompting the company—while disputing the claims—to issue supplemental disclosures to reduce the risk of delay or disruption to the transaction. The company also reported that, following a stop-ship order initiated in November 2025 and a subsequent voluntary recall conducted in consultation with the U.S. Food and Drug Administration, sales of its Brevera 9 Gauge Needles, which represented about 4.7% of Breast Health revenue in fiscal 2025, are expected to be adversely affected for an extended period, making it harder to meet 2026 revenue milestones tied to contingent value rights and reducing the estimated present value of those instruments, while a separate BioZorb product liability litigation involving roughly 200 plaintiffs reached an insurance-covered settlement in principle in November 2025, formalized on January 7, 2026, that is expected—if contingencies are met—to resolve the substantial majority of those cases without financial liability for the company.

The most recent analyst rating on (HOLX) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.

Spark’s Take on HOLX Stock

According to Spark, TipRanks’ AI Analyst, HOLX is a Outperform.

Hologic’s overall stock score is driven by strong technical indicators and a positive corporate event with the acquisition agreement. Financial performance shows stability but highlights areas needing improvement, particularly in profitability and cash flow. The high valuation may pose a risk, but the acquisition premium suggests market confidence.

To see Spark’s full report on HOLX stock, click here.

More about Hologic

Hologic, Inc. is a medical technology company focused on women’s health, with significant operations in breast health, including breast biopsy systems, associated disposable products such as Brevera 9 Gauge Needles, and implantable devices like the BioZorb 3D bioabsorbable marker, which support breast-conserving cancer surgery and related diagnostics.

Average Trading Volume: 2,944,102

Technical Sentiment Signal: Buy

Current Market Cap: $16.74B

For detailed information about HOLX stock, go to TipRanks’ Stock Analysis page.